Newly identified gene signature helps assess cancer risk and optimize treatment
In a paper published in PNAS, Maureen Murphy, Ph.D., Deputy Director of Wistar's Ellen and Ronald Caplan Cancer Center and Ira Brind Professor and Program Leader in the Molecular & Cellular Oncogenesis Program, and team have identified a gene signature that accurately predicts the functioning of P53 variants, important information to assessing cancer risk and optimizing choices for cancer therapeutics.
Andrew Kossenkov Maureen Murphy Wistar Ellen Emily Henderson Cancer Research Cancer Research Industry
Source: news-medical.net